NCT02589977View on ClinicalTrials.gov

Myocardial Perfusion, Oxidative Metabolism, and Fibrosis in HFpEF

PHASE4CompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

January 21, 2020

Study Completion Date

January 21, 2020

Conditions
Heart Failure, DiastolicDiastolic Heart FailureHypertension
Interventions
DRUG

regadenoson

evaluation of myocardial blood flow, interstitial fibrosis and oxidative metabolism in HFpEF, compared to hypertensive and normal participants

Trial Locations (1)

37232

Vanderbilt University Medical Center, Nashville

All Listed Sponsors
collaborator

Astellas Pharma US, Inc.

INDUSTRY

lead

Marvin W. Kronenberg, M.D.

OTHER

NCT02589977 - Myocardial Perfusion, Oxidative Metabolism, and Fibrosis in HFpEF | Biotech Hunter | Biotech Hunter